Xtl Biopharmaceuticals (XTLB) Net Income Growth (1y) (2010 - 2024)
Xtl Biopharmaceuticals (XTLB) Net Income Growth (1y) (2010 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 1,228.66% |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.74% |
| Sep 30, 2024 | 103.48% |
| Jun 30, 2024 | -93.41% |
| Mar 31, 2024 | 152.77% |
| Dec 31, 2023 | 13.36% |
| Sep 30, 2023 | -9.12% |
| Jun 30, 2023 | -27.72% |
| Mar 31, 2023 | -281.62% |
| Dec 31, 2022 | 13.57% |
| Sep 30, 2022 | -13.44% |
| Jun 30, 2022 | 5.94% |
| Mar 31, 2022 | 318.10% |
| Dec 31, 2021 | -194.72% |
| Sep 30, 2021 | 689.86% |
| Jun 30, 2021 | -39.63% |
| Mar 31, 2021 | -234.10% |
| Dec 31, 2020 | 230.21% |
| Sep 30, 2020 | -121.77% |
| Jun 30, 2020 | -8.50% |
| Mar 31, 2020 | 186.93% |